We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Signet Jewelers
SIG
$3.67B
| $60.1M | 0.13% |
543,233
-126,409
| -19% | -$13.2M |
|
|
CEO
152
DELISTED
CNOOC Limited
CEO
| $59.4M | 0.12% |
331,557
+101,830
| +44% | +$17.2M |
|
|
MGLN
153
DELISTED
Magellan Health Services, Inc.
MGLN
| $58.5M | 0.12% |
939,221
+41,870
| +5% | +$2.46M |
|
|
ASA
154
ASA Gold and Precious Metals
ASA
$962M
| $58M | 0.12% |
3,961,439
-308,813
| -7% | -$4.22M |
|
155
Bloomin' Brands
BLMN
$710M
| $57.9M | 0.12% |
+2,580,665
| New | +$57M |
|
|
JNS
156
DELISTED
Janus Capital Group Inc
JNS
| $57.2M | 0.12% |
+4,585,514
| New | +$54M |
|
|
CEE
157
Central and Eastern Europe Fund
CEE
$138M
| $55.3M | 0.12% |
1,979,211
-50,204
| -2% | -$1.32M |
|
158
Kinross Gold
KGC
$28.6B
| $55.1M | 0.12% |
13,310,137
-750,500
| -5% | -$3.05M |
|
159
iShares Core MSCI Emerging Markets ETF
IEMG
$150B
| $55M | 0.12% |
1,064,575
-106,101
| -9% | -$5.39M |
|
160
Viatris
VTRS
$20.4B
| $55M | 0.12% |
1,066,797
+993,053
| +1,347% | +$48.8M |
|
|
CHN
161
DELISTED
China Fund
CHN
| $54.6M | 0.11% |
2,578,359
-63,570
| -2% | -$1.29M |
|
162
Halliburton
HAL
$27.7B
| $54.6M | 0.11% |
768,599
-75,966
| -9% | -$4.87M |
|
163
eBay
EBAY
$48.9B
| $54.1M | 0.11% |
2,567,463
+2,566,745
| +357,485% | +$55.9M |
|
164
Vanguard FTSE Europe ETF
VGK
$30.2B
| $53.5M | 0.11% |
892,011
+18,190
| +2% | +$1.1M |
|
|
MSF
165
DELISTED
Morgan Stanley Emerging Mkts Fd
MSF
| $53.2M | 0.11% |
3,318,619
-153,080
| -4% | -$2.4M |
|
|
RHT
166
DELISTED
Red Hat Inc
RHT
| $52.9M | 0.11% |
956,432
+3,154
| +0.3% | +$160K |
|
|
GF
167
New Germany Fund
GF
$185M
| $52.6M | 0.11% |
2,821,391
-418,443
| -13% | -$7.9M |
|
|
KF
168
Korea Fund
KF
$252M
| $51.7M | 0.11% |
1,209,471
-151,805
| -11% | -$6.31M |
|
169
Wells Fargo
WFC
$265B
| $51.5M | 0.11% |
979,138
+40,838
| +4% | +$2.05M |
|
|
SWZ
170
Swiss Helvetia Fund
SWZ
$76.3M
| $51.2M | 0.11% |
3,510,905
-598,369
| -15% | -$8.6M |
|
171
AT&T
T
$166B
| $50.6M | 0.11% |
1,894,142
-27,273
| -1% | -$731K |
|
|
HOUS
172
DELISTED
Anywhere Real Estate
HOUS
| $49.9M | 0.1% |
1,323,433
+827,206
| +167% | +$32.1M |
|
173
Verizon
VZ
$197B
| $49.1M | 0.1% |
1,002,894
+171,130
| +21% | +$8.29M |
|
|
VALE.P
174
DELISTED
Vale S A
VALE.P
| $49M | 0.1% |
4,118,339
+301,593
| +8% | +$3.67M |
|
175
Adams Diversified Equity Fund
ADX
$3.14B
| $46.1M | 0.1% |
3,354,916
-772,576
| -19% | -$10.3M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.